2 September 2015 - Bristol-Myers Squibb, a global biopharmaceutical company, has received the exclusive right to acquire Promedior and its fibrosis drug, it was reported yesterday.The deal is valued at USD1.25bn. According to the terms of the contract, Bristol-Myers will pay USD150m in cash up front for the right to buy Promedior.Bristol-Myers can exercise its right after Promedior completes either of two phase-two trials for the treatment PRM-151, which is a recombinant form of human pentraxin-2 protein in Phase 2 development for the treatment of idiopathic pulmonary fibrosis and myelofibrosis.